Cargando…
Supplementation with a Highly Concentrated Docosahexaenoic Acid (DHA) in Non-Proliferative Diabetic Retinopathy: A 2-Year Randomized Double-Blind Placebo-Controlled Study
We assessed the effect of a 2-year supplementation with a highly concentrated docosahexaenoic acid (DHA) product with antioxidant activity on non-proliferative diabetic retinopathy (NPDR) in a randomized double-blind placebo-controlled study. A total of 170 patients with diabetes were randomly assig...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772895/ https://www.ncbi.nlm.nih.gov/pubmed/35052620 http://dx.doi.org/10.3390/antiox11010116 |
_version_ | 1784635952386277376 |
---|---|
author | Piñas García, Purificación Hernández Martínez, Francisco Javier Aznárez López, Núria Castillón Torre, Luis Tena Sempere, Mª Eugenia |
author_facet | Piñas García, Purificación Hernández Martínez, Francisco Javier Aznárez López, Núria Castillón Torre, Luis Tena Sempere, Mª Eugenia |
author_sort | Piñas García, Purificación |
collection | PubMed |
description | We assessed the effect of a 2-year supplementation with a highly concentrated docosahexaenoic acid (DHA) product with antioxidant activity on non-proliferative diabetic retinopathy (NPDR) in a randomized double-blind placebo-controlled study. A total of 170 patients with diabetes were randomly assigned to the DHA group (n = 83) or the placebo group (n = 87). NPDR was diagnosed using non-contact slit lamp biomicroscopy examination, and classified into mild, moderate, and severe stages. Patients in the DHA group received a high rich DHA triglyceride (1050 mg/day) nutritional supplement, and those in the placebo group received olive oil capsules. The percentages of mild NPDR increased from 61.7% at baseline to 75.7% at the end of the study in the DHA group, and from 61.9% to 73.1% in the placebo group. Moderate NPDR stages decreased from 35.1% at baseline to 18.7% at the end of the study in the DHA group, and from 36.8% to 26.0% in the placebo group. In the DHA group, there were five eyes with severe NPDR at baseline, which increased to one more at the end of the study. In the placebo group, of two eyes with severe NPDR at baseline, one eye remained at the end of the study. Changes in visual acuity were not found. There were improvements in the serum levels of HbA1c in both groups, but significant differences between the DHA and the placebo groups were not found. In this study, the use of a DHA triglyceride nutraceutical supplement for 2 years did not appear to influence the slowing of the progression of NPDR. |
format | Online Article Text |
id | pubmed-8772895 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87728952022-01-21 Supplementation with a Highly Concentrated Docosahexaenoic Acid (DHA) in Non-Proliferative Diabetic Retinopathy: A 2-Year Randomized Double-Blind Placebo-Controlled Study Piñas García, Purificación Hernández Martínez, Francisco Javier Aznárez López, Núria Castillón Torre, Luis Tena Sempere, Mª Eugenia Antioxidants (Basel) Article We assessed the effect of a 2-year supplementation with a highly concentrated docosahexaenoic acid (DHA) product with antioxidant activity on non-proliferative diabetic retinopathy (NPDR) in a randomized double-blind placebo-controlled study. A total of 170 patients with diabetes were randomly assigned to the DHA group (n = 83) or the placebo group (n = 87). NPDR was diagnosed using non-contact slit lamp biomicroscopy examination, and classified into mild, moderate, and severe stages. Patients in the DHA group received a high rich DHA triglyceride (1050 mg/day) nutritional supplement, and those in the placebo group received olive oil capsules. The percentages of mild NPDR increased from 61.7% at baseline to 75.7% at the end of the study in the DHA group, and from 61.9% to 73.1% in the placebo group. Moderate NPDR stages decreased from 35.1% at baseline to 18.7% at the end of the study in the DHA group, and from 36.8% to 26.0% in the placebo group. In the DHA group, there were five eyes with severe NPDR at baseline, which increased to one more at the end of the study. In the placebo group, of two eyes with severe NPDR at baseline, one eye remained at the end of the study. Changes in visual acuity were not found. There were improvements in the serum levels of HbA1c in both groups, but significant differences between the DHA and the placebo groups were not found. In this study, the use of a DHA triglyceride nutraceutical supplement for 2 years did not appear to influence the slowing of the progression of NPDR. MDPI 2022-01-05 /pmc/articles/PMC8772895/ /pubmed/35052620 http://dx.doi.org/10.3390/antiox11010116 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Piñas García, Purificación Hernández Martínez, Francisco Javier Aznárez López, Núria Castillón Torre, Luis Tena Sempere, Mª Eugenia Supplementation with a Highly Concentrated Docosahexaenoic Acid (DHA) in Non-Proliferative Diabetic Retinopathy: A 2-Year Randomized Double-Blind Placebo-Controlled Study |
title | Supplementation with a Highly Concentrated Docosahexaenoic Acid (DHA) in Non-Proliferative Diabetic Retinopathy: A 2-Year Randomized Double-Blind Placebo-Controlled Study |
title_full | Supplementation with a Highly Concentrated Docosahexaenoic Acid (DHA) in Non-Proliferative Diabetic Retinopathy: A 2-Year Randomized Double-Blind Placebo-Controlled Study |
title_fullStr | Supplementation with a Highly Concentrated Docosahexaenoic Acid (DHA) in Non-Proliferative Diabetic Retinopathy: A 2-Year Randomized Double-Blind Placebo-Controlled Study |
title_full_unstemmed | Supplementation with a Highly Concentrated Docosahexaenoic Acid (DHA) in Non-Proliferative Diabetic Retinopathy: A 2-Year Randomized Double-Blind Placebo-Controlled Study |
title_short | Supplementation with a Highly Concentrated Docosahexaenoic Acid (DHA) in Non-Proliferative Diabetic Retinopathy: A 2-Year Randomized Double-Blind Placebo-Controlled Study |
title_sort | supplementation with a highly concentrated docosahexaenoic acid (dha) in non-proliferative diabetic retinopathy: a 2-year randomized double-blind placebo-controlled study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772895/ https://www.ncbi.nlm.nih.gov/pubmed/35052620 http://dx.doi.org/10.3390/antiox11010116 |
work_keys_str_mv | AT pinasgarciapurificacion supplementationwithahighlyconcentrateddocosahexaenoicaciddhainnonproliferativediabeticretinopathya2yearrandomizeddoubleblindplacebocontrolledstudy AT hernandezmartinezfranciscojavier supplementationwithahighlyconcentrateddocosahexaenoicaciddhainnonproliferativediabeticretinopathya2yearrandomizeddoubleblindplacebocontrolledstudy AT aznarezlopeznuria supplementationwithahighlyconcentrateddocosahexaenoicaciddhainnonproliferativediabeticretinopathya2yearrandomizeddoubleblindplacebocontrolledstudy AT castillontorreluis supplementationwithahighlyconcentrateddocosahexaenoicaciddhainnonproliferativediabeticretinopathya2yearrandomizeddoubleblindplacebocontrolledstudy AT tenasemperemaeugenia supplementationwithahighlyconcentrateddocosahexaenoicaciddhainnonproliferativediabeticretinopathya2yearrandomizeddoubleblindplacebocontrolledstudy |